InnoCare Wins Three Awards

Shanghai June 10, 2021—— InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, won three awards at the First Drug Innovation Forum and Awards Ceremony organized by Securities Times, a media under the People’s Daily. InnoCare was awarded as “2020 Top 10 Companies in Drug Innovation”, and InnoCare’s BTK inhibitor orelabrutinib was selected as the “2020 Drug Innovation Achievement Award”. At the same time, Dr. Jasmine Cui, the Co-founder, Chairwoman and CEO of InnoCare, was honored as the “2020 Top 10 Drug Innovation Leader”.

InnoCare: 2020 Top 10 Companies in Drug Innovation

InnoCare was founded in August 2015. By now, InnoCare has established an experienced and innovative R&D and clinical development team. Currently InnoCare has developed a pipeline with over 10 innovative drugs in the field of cancer and autoimmune diseases.

Orelabrutinib: 2020 Drug Innovation Achievement Award

Orelabrutinib is a highly selective and novel BTK inhibitor that can avoid off-target-related adverse events with improved safety and efficacy. On December 25, 2020, orelabrutinib received approval from the NMPA in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL), and the treatment of patients with relapsed/refractory MCL. In addition, orelabrutinib shows potentials in the treatment for autoimmune diseases, with phase II of clinical trials for Multiple sclerosis (MS) globally.

Dr. Jasmine Cui: 2020 Top 10 Drug Innovation Leader

Dr. Jasmine Cui, the Co-founder, Chairwoman and CEO of InnoCare, was honored the “2020 Top 10 Drug Innovation Leader”. As a female entrepreneur, Dr. Jasmine Cui has been leading the company to forge ahead and developed a strong team and rich product pipeline. In March 2020, InnoCare was successfully listed on the Hong Kong Stock Exchange despite the outbreak of the epidemic.

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.